Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
Publication/Presentation Date
4-15-2007
Abstract
Despite the well-recognized role of platelets in the pathogenesis of acute myocardial infarction (AMI) and in the vascular responses to angioplasty, the relation between platelet count and outcomes after primary percutaneous coronary intervention (PCI) in AMI is unknown. We therefore determined the effect of baseline platelet count on clinical and angiographic outcomes of patients with AMI undergoing primary PCI. In the prospective, randomized CADILLAC trial, platelet count on admission was available in 2,021 of 2,082 patients (97.0%). Angiographic results and outcomes at 30 days and 1 year were stratified by quartiles of platelet count. Median platelet count was 231 x 10(9)/L (range 38 to 709). Primary PCI angiographic success rates were independent of platelet count. The 30-day incidence of target vessel thrombosis or reocclusion increased steadily across the higher quartiles of baseline platelet count (0.2%, 0.6%, 1.0%, and 2.0%, p = 0.027). At 1 year, patients with a baseline platelet count >or=234 versus10(9)/L had higher rates of death or reinfarction (8.9% vs 4.5%, p
Volume
99
Issue
8
First Page
1055
Last Page
1061
ISSN
0002-9149
Published In/Presented At
Nikolsky, E., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Sadeghi, M., Mehran, R., Lansky, A. J., Na, Y., & Stone, G. W. (2007). Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). The American journal of cardiology, 99(8), 1055–1061. https://doi.org/10.1016/j.amjcard.2006.11.066
Disciplines
Medicine and Health Sciences
PubMedID
17437727
Department(s)
Department of Medicine
Document Type
Article